Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN HSESHENG LIN and JOE Y CHANG.
Connection Strength
4.977
-
Esophageal cancer: diagnosis and management. Chin J Cancer. 2010 Oct; 29(10):843-54.
Score: 0.376
-
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
Score: 0.228
-
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117.
Score: 0.217
-
A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):977-988.
Score: 0.211
-
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Front Oncol. 2021; 11:748331.
Score: 0.202
-
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457.
Score: 0.201
-
Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol. 2021 May; 28:54-61.
Score: 0.194
-
Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol. 2020 Jul-Aug; 5(4):700-704.
Score: 0.183
-
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
Score: 0.181
-
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
Score: 0.177
-
Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. J Thorac Oncol. 2020 01; 15(1):101-109.
Score: 0.174
-
Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 07; 20(4):e480-e488.
Score: 0.169
-
Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. Int J Part Ther. 2018; 5(2):18-27.
Score: 0.166
-
Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
Score: 0.157
-
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
Score: 0.151
-
Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):58-65.
Score: 0.150
-
Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
Score: 0.150
-
Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1226-35.
Score: 0.137
-
Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016 Mar; 43(3):1111-8.
Score: 0.137
-
Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol. 2013 Dec; 8(12):1484-91.
Score: 0.117
-
Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70.
Score: 0.113
-
Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75.
Score: 0.112
-
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
Score: 0.107
-
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
Score: 0.059
-
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Res. 2024 Jan; 44(1):133-137.
Score: 0.059
-
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 07; 5(7):e404-e420.
Score: 0.057
-
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540.
Score: 0.055
-
Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022 11; 176:149-156.
Score: 0.054
-
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):676-683.
Score: 0.054
-
Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol. 2022 Apr; 61(4):403-408.
Score: 0.051
-
Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 09; 22(5):e745-e755.
Score: 0.048
-
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.
Score: 0.047
-
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475.
Score: 0.047
-
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2).
Score: 0.047
-
Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7.
Score: 0.046
-
Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):897-908.
Score: 0.046
-
Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol. 2020 04; 43(4):231-235.
Score: 0.045
-
Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107.
Score: 0.044
-
Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):324-329.
Score: 0.044
-
Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):63-71.
Score: 0.035
-
Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
Score: 0.034
-
Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
Score: 0.031
-
Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60.
Score: 0.031
-
Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014 Sep; 9(9):1398-405.
Score: 0.031